CS Paper Radar

A Trustworthy Clinical Decision Support Framework for Brain Tumor MRI Classification: Integrating Attention-Guided Learning, Explainable AI, and Out-of-Distribution Validation

Arjun Kumar Gupta, Harminder Pal Monga

cs.CV cs.AIcs.LG ·submitted 2026-10-06 20:41 UTC · v1
publishedbenchmark

Abstract

Deep learning models for brain tumor diagnosis need to do more than achieve high classification accuracy. For practical use, they should also provide understandable predictions, recognize unsuitable inputs, and work within a usable clinical system. This paper presents a framework for classifying brain MRI into four categories: glioma, meningioma, pituitary tumor, and no tumor. The model uses InceptionResNetV2 with a Convolutional Block Attention Module (CBAM), while Grad-CAM provides visual explanations of its predictions. A two-stage out-of-distribution (OOD) mechanism screens unsuitable inputs using an initial grayscale check followed by Mahalanobis distance, softmax confidence, and predictive entropy. These components are brought together in NeuroScan AI, a real-time web application. Evaluated on a Mendeley brain tumor MRI dataset of 12,064 images, the framework achieved 98.70% validation accuracy, 96.73% test accuracy, and a macro-average AUC of 0.9965. The OOD pipeline achieved 99% detection accuracy on a preliminary 100-image benchmark. Grad-CAM visualizations showed qualitative correspondence with clinically established tumor locations across all four classes. Overall, the work brings classification, explainability, input validation, and deployment into one framework, while recognizing that broader clinical and OOD validation is still required.

Comment
Accepted for presentation at the IC3AI-2026 IEEE conference in Dec 2026. It has been accepted/selected but is not yet published. 6 pages, 4 figures, 6 tables

Closest papers

Nearest neighbours by meaning across the whole index.

BrainAid: Efficient Brain Tumor Detection Using Lightweight CNNs and Explainable AI for Resource-Constrained Environments

cs.CV ·2026-10-10 ·Sai Sriram Gonthina, Ross Gore, Bikash Chandra Singh, Pronaya Bhattacharya, Sachin Shetty +2 more
similarity 0.83
Abstract

A brain tumor is an unusual growth of cells in the brain that can be cancerous or not, affecting normal brain function and causing serious risk to health. Existing solutions for brain tumor classification, such as expert manual evaluations of magnetic resonance imaging (MRI) scans, are generally inconsistent as different professionals have different criteria and can be resource-intensive, leading to delayed diagnoses. Additionally, while deep learning models have demonstrated potential, they typically require significant computational resources, motivating the need for more efficient and accessible diagnostic tools that can be deployed in real-time healthcare settings. To address these limitations, this study presents BrainAid, which makes efficient use of Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) for effective classification of four-class classification of glioma, meningioma, pituitary tumor, and no-tumor MRI scans, outperforming all the standard models such as VGG16, Inception-V3, ResNet-50 and so, while integrating Explainable AI (XAI) to improve interpretability. The BrainAid is trained to classify tumors with a high precision of 98%, achieving an F1 score of 98% and an accuracy of 98% using publicly available dataset. The model is deployed on a Raspberry Pi, demonstrating efficiency in low-resource environments. This system shows the feasibility of real-time, edge-based tumor classification, providing quick diagnostic support for medical professionals and enhancing patient care in resource-limited healthcare facilities and underserved areas.

0.07

Explainable and CPU-Efficient Brain Tumor Classification from MRI Using Two-Phase EfficientNetB3 Fine-Tuning

cs.CV ·2026-11-18 ·Deepro Das, Saad Kabir Uddin, Mohammad Alauddin, Bornali Sarker, Thasnim Akhter
similarity 0.77
Abstract · 6 pages, 5 figures, 6 tables

Brain tumors are among the most lethal neurological disorders, with over 308,000 new diagnoses annually worldwide. Accurate classification of tumor type from Magnetic Resonance Imaging (MRI) scans is critical for treatment planning; however, manual radiological interpretation is time-consuming and prone to inter-observer variability. This paper proposes an automated deep learning pipeline for four-class brain MRI classification (glioma, meningioma, no tumor, and pituitary tumor) using EfficientNetB3 transfer learning with a custom classification head. A two-phase training strategy is adopted: Phase 1 trains the head with a frozen backbone (best validation accuracy: 92.77%), and Phase 2 selectively fine-tunes the top 37 layers at a 100x reduced learning rate (best validation accuracy: 94.91%). On an independent balanced test set of 1,600 MRI images, the system achieves 90.62% overall accuracy and a macro-average AUC of 0.9854. Gradient-weighted Class Activation Mapping (Grad-CAM) is integrated for class-discriminative visual explainability. The proposed system simultaneously addresses three dimensions absent in prior work: high accuracy, CPU-only computational efficiency, and clinical interpretability.

0.14

Benchmarking CNNs, Vision Transformers, and Foundation Models for Explainable Brain Tumor MRI Classification: Calibration, Decision Analysis, and External Validation

cs.CV ·2026-11-09 ·Akwasi Asare
similarity 0.75
Abstract · Under review at Scientific Report Journal, Springer

Deep learning models for brain tumor MRI classification are usually compared by accuracy alone, on public datasets whose independence is rarely checked. We benchmarked six architectures: two convolutional networks (EfficientNetV2-M and ConvNeXt-V2-Tiny), two vision transformers (Swin-V2-S and ViT-L/16), and two foundation models (DINOv2-L and MedSigLIP-448), for four-class classification of 7,216 public MRI images. We assessed accuracy, calibration, explainability, ensembles, and decision curves, with every fitted quantity estimated on validation data only. Pixel-verified duplicate screening showed that 36% of the test images had a near-duplicate in the training data. Test accuracy ranged from 94.5% to 95.6%, with no pairwise difference after Holm correction, and fell to 90.3% to 91.7% on the 773 test images free of duplicates and shared patients. Ensembles did not outperform the best single model. Attribution maps passed a model-randomization test but localized expert-annotated tumors poorly. On 1,675 external BDNeuro-MRI images that did not duplicate the training data, accuracy ranged from 77.6% (MedSigLIP-448) to 95.0% (ViT-L/16), and 12 of 15 pairwise differences were significant. Internal accuracy on this public collection therefore did not distinguish the architectures, whereas the duplicate-filtered external test did.

0.15

A Tumour-Aware Multimodal Framework for Explainable Prediction of IDH Mutation in Gliomas from Multi-Sequence MRI

eess.IV cs.CV ·2026-11-13 ·Tahsien Al-Quraishi, Waseem Alwan Zaboon, O. S. Albahri, Raza Nowrozy
similarity 0.71
Abstract · 45 pages, 12 figures, 4 tables. Preprint of an article submitted for consideration in International Journal of Information Technology & Deci…

Accurate prediction of isocitrate dehydrogenase (IDH) mutation status is essential for glioma diagnosis, prognosis, and treatment planning. Although recent deep learning approaches have demonstrated promising performance, many rely on whole-brain feature extraction and provide limited interpretability. This study proposes a tumour-aware multimodal framework for explainable, non-invasive prediction of IDH mutation status from multiparametric magnetic resonance imaging (MRI). The proposed framework integrates four MRI sequences (T1, T1CE, T2, and FLAIR), tumour subregion segmentation, quantitative radiomic descriptors, and clinical information within a unified deep learning architecture. An ablation study was conducted to evaluate the contribution of tumour-aware learning, radiomic features, and clinical variables. Model performance was assessed using multiple complementary evaluation metrics, including accuracy, precision, recall, F1-score, balanced accuracy, receiver operating characteristic analysis, confusion matrix evaluation, and Grad-CAM visualisation. Experimental results demonstrated that the proposed multimodal framework consistently outperformed the baseline MRI-only model, with the Clinical Fusion model achieving the strongest overall predictive performance. The integration of tumour-aware learning, radiomic descriptors, and clinical information progressively improved classification performance, while Grad-CAM visualisations indicated that the model predominantly focused on biologically relevant tumour regions. These findings suggest that tumour-aware multimodal feature integration enables accurate, interpretable, and non-invasive molecular profiling of gliomas and provides a promising foundation for future clinical decision support in precision neuro-oncology.

0.12

Quality-Governed Deep Learning Network for Brain Tumor MRI Segmentation

cs.CV cs.AI ·2026-11-03 ·Asifiqbal Saiyed, Nitesh Chilakala, Jimmy Joseph, Praneetha Goli, Rohini Maskar
published similarity 0.70
Abstract

The segmentation of brain tumors from magnetic resonance imaging (MRI) is an essential step for computer-aided neuro-oncology, treatment planning and follow-up. While effective encoder-decoder representations are achieved by U-Net and Attention U-Net, the skip sections of the network can generate weak-contrast or noisy responses in the case of heterogeneous boundaries of the tumor. In this paper, we introduce a Quality-Governed Deep Learning Network (QGDL-Net) that can be used for binary tumor segmentation from FLAIR MRI slices. The proposed model is able to predict the slice quality based on contrast and SNR statistics and to fine-tune the encoder features prior to decoding by learnable quality gates. We used the 80:20 train-validation split for experiments with BraTS 2021. QGDL-Net achieved a Dice of 0.9747, IoU of 0.9506, precision of 0.9755, recall of 0.9739, F1 of 0.9747 and accuracy of 0.9982, outperforming U-Net and Attention U-Net. The EigenCAM maps and segmentation overlays provide better tumor localization and interpretable activation around the lesion regions.

0.30

Towards Trustworthy AI for Glioma Diagnosis: A Task-Aware Evaluation of Uncertainty Quantification

cs.CV cs.AI ·2026-09-30 ·Gonzalo Esteban Mosquera Rojas, Sebastian R. van der Voort, Carolin M. Pirkl, Sandeep Kaushik, Marion Smits +1 more
top venue similarity 0.69
Abstract · Accepted for publication at the Journal of Machine Learning for Biomedical Imaging (MELBA) https://melba-journal.org/2026:033

Uncertainty Quantification (UQ) is a key requirement for trustworthy AI in high-stakes medical image analysis. In this work, we evaluate UQ in a multi-task Deep Learning framework for MRI-based glioma diagnosis that performs tumor segmentation and predicts IDH mutation status, 1p/19q co-deletion status, and tumor grade. Monte Carlo Dropout (MCD) is used for a detailed task-aware analysis of predictive, aleatoric, and epistemic uncertainty. We assess MC sample convergence, calibration, error detection, selective prediction, associations with segmentation performance, and the effect of voxel-wise uncertainty aggregation on case-level reliability. We also compare MCD with Deep Ensembles (DE) and Monte Carlo Deep Ensembles (MCDE), examine interactions between segmentation quality and classification, and evaluate a composite trust score integrating segmentation and classification uncertainty. Across tasks, uncertainty estimates supported meaningful error detection, while calibration depended on the dropout rate, with moderate rates yielding the most reliable probabilities. Uncertainty decomposition provided task-dependent interpretability but did not consistently improve error detection over predictive uncertainty alone. DE and MCDE showed comparable operational utility, with no method consistently dominating across tasks and metrics. The composite trust score did not consistently outperform classification uncertainty for selective prediction. Overall, our results provide a task-aware evaluation strategy and practical guidance for the development of trustworthy AI for glioma diagnosis.

0.41

Does DCGAN-Based Synthetic Augmentation Improve Brain Tumor MRI Classification? An Empirical Study

eess.IV cs.CV ·2026-09-20 ·Irhum Jawad Khan, Talha bin Aslam
similarity 0.68
Abstract

Generative adversarial networks (GANs) are increasingly used to augment medical imaging datasets, but synthetic images do not necessarily provide downstream classification benefits. This study investigates whether class-specific Deep Convolutional Generative Adversarial Network (DCGAN) augmentation improves brain tumor classification when the classifier and evaluation set are held constant. Experiments were conducted on 7,200 brain magnetic resonance imaging (MRI) scans across four classes: glioma, meningioma, pituitary tumor, and no tumor. For each class, 1,400 real images were used for training and 400 were reserved for testing. A baseline Swin Transformer classifier was trained using only the real training images and compared with a second model trained using the same real images augmented with 500 DCGAN-generated images per class. Both conditions were evaluated on the identical held-out test set. The two models achieved the same overall accuracy of 96%, while macro F1 remained effectively unchanged and ROC-AUC decreased slightly from 0.987 to 0.982 after augmentation. Class-level analysis showed small redistributions in errors rather than a consistent performance gain. FID values between real and synthetic images ranged from 209.15 to 314.27, indicating substantial distributional differences under the adopted evaluation setup. These results suggest that synthetic augmentation should not be assumed to improve medical image classification and should instead be evaluated for both distributional fidelity and downstream task utility.

0.18

Evaluating Single and Multi-Omics Based Explainable Artificial Intelligence (MOXAI) for Molecular Subclass Classification of Adult-Type Diffuse Gliomas

cs.CV cs.AI ·2026-09-26 ·Md Zahangir Alom, Quynh T. Tran, Breuer Alexandar, Brent A. Orr
similarity 0.68
Abstract · 8 pages, 6 figures

DNA methylation (DNAM) profiling has emerged as a powerful diagnostic tool for classifying brain and solid tumors. However, existing computational models typically analyze methylation and copy number variation (CNV) data separately, failing to capture the complementary information their integration could provide. Moreover, current classification models lack mechanisms for within-class risk assessment analogous to traditional tumor grading, and no established explainability method can attribute classification decisions to specific genomic loci. In this paper, we present MOXAI (Multi-Omics Based Explainable AI), a deep learning framework that integrates DNA methylation and copy number data from methylation arrays to classify molecular subtypes of adult-type diffuse gliomas, alongside single-modality variants for comparison. Using a cohort from The Cancer Genome Atlas (TCGA), we trained ResNet50, DINOv2, and Graph Attention Network (GAT) models on methylation data alone, copy number data alone, and combined multimodal data. We further developed explainable AI (XAI) methods based on class activation maps (CAMs) and gradient-weighted CAM (Grad-CAM) to identify the specific CpG sites, genes, and chromosomal regions most relevant to each classification decision. The multimodal model achieved up to 92.98% cross-validation accuracy, outperforming models trained on CNV data alone. DINOv2 showed the strongest generalization, reaching 94.25% accuracy (confidence >0.9) on independent validation sets. XAI results aligned with established molecular features of adult-type diffuse glioma subtypes, confirming the biological interpretability of the framework.

0.14